Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows

Author(s): D. Sorrentino, A. Paviotti, G. Fiorino.

Journal Name: Current Drug Targets

Volume 11 , Issue 2 , 2010

Become EABM
Become Reviewer

Abstract:

Recurrence of Crohns disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients ’ management and, ultimately, highlight the molecular mechanisms at the very basis of Crohns disease.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 11
ISSUE: 2
Year: 2010
Page: [219 - 226]
Pages: 8
DOI: 10.2174/138945010790309920
Price: $58

Article Metrics

PDF: 4